Peer Exchange

  

Management of Cardiac Amyloidosis


Key opinion leaders consider the diagnostic workup for differentiating patients referred with general amyloidosis.

A discussion on the historical prognosis of hypertrophic cardiomyopathy with conventional management.

A discussion on the subtle diagnosis of immunoglobulin light chain amyloidosis and transthyretin amyloidosis, with consideration for echocardiogram features and noncardiac biopsy.

Experts in the field of cardiac amyloidosis management discuss when heart biopsies are necessary and consider possible adverse events.

The benefits of using technetium pyrophosphate scans to diagnose cardiac amyloidosis and the prevalence of transthyretin amyloidosis.

The importance of lab testing for monoclonal proteins to interpret the results of technetium pyrophosphate scans and the significance of wild-type transthyretin amyloidosis. 

The significance of technetium pyrophosphate scans and wild-type disease when considering TAVR. 

A strategy for prognosticating patients with immunoglobulin light chain amyloidosis and transthyretin amyloidosis.

 Key opinion leaders discuss modifying treatment plans for patients with immunoglobulin light-chain amyloidosis and transthyretin amyloidosis who poorly tolerate initial therapy. 

A discussion on the effectiveness of cardioversion or atrial fibrillation ablation to control heart rhythm in patients with cardiac amyloidosis.

When to use pacemakers and defibrillators for patients with cardiac amyloidosis disease subtypes.

A discussion on decision factors for selecting therapy to manage congestive heart failure and an overview of available agents. 

Key opinion leaders provide an overview of available selective stabilizers for transthyretin amyloidosis.

Key opinion leaders consider the use of nonsteroidal anti-inflammatory drugs to treat cardiomyopathy. 
SAP Partner Banner